Literature DB >> 23235755

Long-term complications in Hodgkin's lymphoma survivors.

Saadettin Kilickap1, Ibrahim Barista, Sukran Ulger, Ismail Celik, Ugur Selek, Ibrahim Güllü, Ferah Yildiz, Ayse Kars, Yavuz Ozisik, Gülten Tekuzman.   

Abstract

Background. Although patients with Hodgkin's lymphoma (HL) achieve prolonged survival, long-term complications are a major cause of morbidity and mortality among long-term survivors of HL. Methods. We retrospectively evaluated long-term complications in 336 HL survivors treated between January 1990 and January 2006 at the Department of Medical Oncology of the Hacettepe University Institute of Oncology who were >16 years old at presentation. All patients were regularly followed up every 3 months for the first 2 years after complete response, biannually for 3 years, and annually after 5 years. Results. Median follow-up was 8.5 years. The mean age (±SD) of the patients at the time of diagnosis was 35.7 ± 13.1 years. The male to female ratio was 61%/39%. During follow-up, 29 second malignancies (8.6%) were diagnosed in 28 patients with HL; 22 were solid tumors and 7 were hematological malignancies. Forty-seven (14.0%) of all patients with HL were found to have thyroid abnormalities. During follow-up, 54 (16.1%) patients developed cardiovascular complications. Overall, 29 (8.6%) patients developed late pulmonary toxicities. The cumulative number of chronic viral infections was 13 (3.9%). Conclusions. Long-term survivors of HL need to be properly followed up not only for disease control but also for evaluation of possible late morbidities to minimize the consequences.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23235755     DOI: 10.1177/030089161209800510

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916


  1 in total

1.  Evaluating the Survival Rate and the Secondary Malignancies after Treating Hodgkin's Lymphoma Patients with Chemotherapy Regimens.

Authors:  Ahmad Ahmadzadeh; Mir Saeed Yekaninejad; Mohamad H Jalili; Mohammad Bahadoram; Mehdi Efazat; Mohammad Seghatoleslami; Fatemeh Yazdi; Mozhdeh Mahdipour; Armita Valizadeh; Najmaldin Saki
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2014
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.